Omalizumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Omalizumab" in French language version.

refsWebsite

Global rank French rank

4^th place

12^th place

3jacionline.org

low place

7,597^th place

222^nd place

129^th place

1expert-reviews.com

low place

low place

2,374^th place

298^th place

68^th place

67^th place

europa.eu

ema.europa.eu

(en) « European Medicines Agency - - Xolair », 24 janvier 2014 (consulté le 6 mars 2014)

expert-reviews.com

(en) Tan R, Corren J. « Omalizumab in the treatment of asthma » Expert Review of Respiratory Medicine 2011;5:747-56. PMID 22082161

jacionline.org

(en) Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S, « Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function » J Allergy Clin Immunol. 2004;114:527-30. PMID 15356552
(en) Ong YE, Menzies-Gow A, Barkans J et al. « Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge » J Allergy Clin Immunol. 2005;116:558-64. PMID 16159624
(en) Busse W, Buhl R, Fernandez Vidaurre C. et al. « Omalizumab and the risk of malignancy: results from a pooled analysis » J Allergy Clin Immunol. 2012;129:983-9. PMID 22365654

nejm.org

(en) Maurer M, Rosén K, Hsieh HJ. et al. « Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria » N Eng J Med. 2013;368:924-35. PMID 23432142

nih.gov

ncbi.nlm.nih.gov

(en) Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S, « Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function » J Allergy Clin Immunol. 2004;114:527-30. PMID 15356552
(en) Ong YE, Menzies-Gow A, Barkans J et al. « Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge » J Allergy Clin Immunol. 2005;116:558-64. PMID 16159624
(en) Tan R, Corren J. « Omalizumab in the treatment of asthma » Expert Review of Respiratory Medicine 2011;5:747-56. PMID 22082161
(en) Kopp MV, Hamelmann E, Zielen S, Kamin W et al. « Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma » Clin Exp Allergy 2009;39271–9. PMID 19016798
(en) Maurer M, Rosén K, Hsieh HJ. et al. « Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria » N Eng J Med. 2013;368:924-35. PMID 23432142
(en) Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. « Safety and tolerability of omalizumab » Clin Exp Allergy 2009;39:788-97. PMID 19302249
(en) Busse W, Buhl R, Fernandez Vidaurre C. et al. « Omalizumab and the risk of malignancy: results from a pooled analysis » J Allergy Clin Immunol. 2012;129:983-9. PMID 22365654

wiley.com

onlinelibrary.wiley.com

(en) Kopp MV, Hamelmann E, Zielen S, Kamin W et al. « Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma » Clin Exp Allergy 2009;39271–9. PMID 19016798
(en) Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. « Safety and tolerability of omalizumab » Clin Exp Allergy 2009;39:788-97. PMID 19302249